Researchers detect the most efficient salivary biomarkers for detecting oral cancer

November 15, 2018, Asociacion RUVID
A patient at the CEU's dental clinic. Credit: Asociación RUVID

Over 90 percent of malign tumours in the head and neck are originated from carcinomas of squamous cells that appear in superficial areas of the oral cavity. Their detection with salivary biomarkers can contribute to early treatment, before they transform into tumours. Researchers at the Oral Microbiology Research Group of the CEU Cardenal Herrera university (CEU UCH) in Valencia, Spain, have conducted a systematic review and a meta-analysis of the salivary markers that show the highest efficacy for the early detection of oral cancer in different clinical trials. The results have just been published in the Journal of Oral Pathology and Medicine, the official magazine of the International Association of Oral Pathogens in the field of Dentistry, Oral Surgery and Medicine.

According to Verónica Veses, head researcher of the Group and professor at the Biomedical Sciences Department of the CEU UCH, "detection of this type of in the surface of the mouth essentially depends of the visual examination on behalf of oral health professionals. This is why it is important to find new diagnostic methods to help with accurate early detection. Specially if we take into account that oral cancer is the most common of the tumours in the head and neck, and which is increasingly prevalent among the young population due to the consumption of tobacco and alcohol."

Three types of biomarkers

The research team headed by Dr. Veses has conducted a systematic review and a meta-analysis of the clinical trials that have thus far evaluated the efficacy of the three types of that are the most promising for the early detection of this type of . These salivary markers are two types of cytokines, proteins involved in cellular proliferation and differentiation; two markers that are present in the ribonucleic acid that transfers the genetic code, the messenger RNA or mRNA (DUSP‐1 and S100P); and two more in the micro-RNA (miRNA) of the saliva, but which require further research.

Both mRNA biomarkers have shown to be the most efficient for the of oral squamous cell carcinoma and of neck and head cancer, when comparing the results obtained in the 17 clinical trials reviewed during the research. These tests were chosen as appropriate for the study among those published after the year 2000 in the international database Medline and the international registry of : the Central Register of Controlled Trials.

Explore further: Review: methodological limitations for OSCC biomarkers

More information: Fariah I. Gaba et al. Salivary biomarkers and their efficacies as diagnostic tools for Oral Squamous Cell Carcinoma: Systematic review and meta-analysis, Journal of Oral Pathology & Medicine (2018). DOI: 10.1111/jop.12791

Related Stories

Review: methodological limitations for OSCC biomarkers

December 5, 2016
(HealthDay)—Methodological concerns have limited the analysis of saliva-based biomarkers for oral squamous cell carcinoma (OSCC), according to a review published online Nov. 29 in Head and Neck.

Scientist seeks solutions for cancer patients with dry mouth

August 8, 2018
For several years, Wilmot Cancer Institute scientist Catherine Ovitt, Ph.D., has been investigating ways to protect and regenerate the salivary gland, which can be damaged during radiation treatment for head and neck cancer. ...

Oncogenic oral HPV DNA detected in 3.5 percent of adults

October 20, 2017
(HealthDay)—Men have a higher prevalence of oncogenic oral human papillomavirus (HPV) than women, and prevalence increases with the number of lifetime oral sexual partners and tobacco use, according to a study published ...

Study examines chronic inflammation in oral cavity and HPV status of head and neck cancers

June 18, 2012
Among patients with head and neck squamous cell carcinomas, a history of chronic inflammation in the mouth (periodontitis, i.e. gum disease) may be associated with an increased risk of tumors positive for human papillomavirus ...

Recommended for you

10-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

December 17, 2018
Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal ...

Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers

December 17, 2018
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially ...

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.